Laurus Labs Board approves investment of €9.8M in its joint venture KRKA Pharma Private Limited.
Co-venturer KRKA d.d. will invest €10.2M, maintaining the existing 51:49 shareholding ratio.
Funds will be used by KRKA for capex to set up a new pharmaceutical manufacturing facility.
The investment is a cash consideration for equity shares and is expected in FY 2026-27.